CoChat

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Melanomas that result from mutations in the gene encoding BRAF often become resistant to BRAF inhibition (BRAFi), with multiple mechanisms contributing to resistance. While therapy-induced autophagy promotes resistance to a number of therapies, especially those that target PI3K/mTOR signaling, its role as an adaptive resistance mechanism to BRAFi is not well characterized. Using tumor biopsies from BRAF(V600E) melanoma patients treated either with BRAFi or with combined BRAF and MEK inhibition, we found that BRAFi-resistant tumors had increased levels of autophagy compared with baseline. Patients with higher levels of therapy-induced autophagy had drastically lower response rates to BRAFi and a shorter duration of progression-free survival. In BRAF(V600E) melanoma cell lines, BRAFi or BRAF/MEK inhibition induced cytoprotective autophagy, and autophagy inhibition enhanced BRAFi-induced cell death. Shortly after BRAF inhibitor treatment in melanoma cell lines, mutant BRAF bound the ER stress gatekeeper GRP78, which rapidly expanded the ER. Disassociation of GRP78 from the PKR-like ER-kinase (PERK) promoted a PERK-dependent ER stress response that subsequently activated cytoprotective autophagy. Combined BRAF and autophagy inhibition promoted tumor regression in BRAFi-resistant xenografts. These data identify a molecular pathway for drug resistance connecting BRAFi, the ER stress response, and autophagy and provide a rationale for combination approaches targeting this resistance pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci70454

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 490

Metadata

Authors
Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., Lazova, R., Klump, V., Pawelek, J. M., Xu, X., Xu, W., Schuchter, L. M., Davies, M. A., Herlyn, M., Winkler, J., Koumenis, C., & Amaravadi, R. K.
Affiliations
  • University of Pennsylvania (US)
  • The Wistar Institute (US)
  • Yale University (US)
  • Abramson Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
Venue
Journal of Clinical Investigation
Published
2014-02-24
Volume
124
Issue
3
Pages
1406-1417
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2119735934
Cited by
457
References
52
Citations by year
2026: 11 · 2025: 36 · 2024: 39 · 2023: 27 · 2022: 37 · 2021: 40 · 2020: 40 · 2019: 35 · 2018: 44 · 2017: 44 · 2016: 48 · 2015: 31 · 2014: 24
FWCI
20.08
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Pennsylvania
  • National Institutes of Health
  • National Cancer Institute (P01CA114046, R01CA139362, K01CA175269, K23CA120862, R01CA169134, R01CA094214, P30CA016672, P30CA010815, P30CA016520)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
melanoma, BRAF inhibitor resistance, BRAF V600E mutation, endoplasmic reticulum stress, autophagy, cytoprotective autophagy, GRP78, PERK, MEK inhibition, autophagy inhibition, combination therapy, PI3K/mTOR signaling, progression-free survival
MeSH terms
Vemurafenib, Endoplasmic Reticulum Chaperone BiP, Animals, Antineoplastic Agents, Autophagy, Humans, Indoles, Melanoma, Mice, Nude, Sulfonamides, Drug Resistance, Neoplasm, Mutation, Missense, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.